340 related articles for article (PubMed ID: 24103217)
1. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.
Knezevic D; Goddard AD; Natraj N; Cherbavaz DB; Clark-Langone KM; Snable J; Watson D; Falzarano SM; Magi-Galluzzi C; Klein EA; Quale C
BMC Genomics; 2013 Oct; 14():690. PubMed ID: 24103217
[TBL] [Abstract][Full Text] [Related]
2. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
Clark-Langone KM; Sangli C; Krishnakumar J; Watson D
BMC Cancer; 2010 Dec; 10():691. PubMed ID: 21176237
[TBL] [Abstract][Full Text] [Related]
3. Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue.
Medlow PW; Steele CJ; McCavigan AM; Reardon W; Brown CM; Lambe SM; Ishiy FAA; Walker SM; Logan GE; Raji OY; Berge V; Katz B; Kay EW; Sheehan K; Watson RW; Harkin DP; Kennedy RD; Knight LA
BMC Med Genomics; 2018 Dec; 11(1):125. PubMed ID: 30591067
[TBL] [Abstract][Full Text] [Related]
4. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.
Cronin M; Sangli C; Liu ML; Pho M; Dutta D; Nguyen A; Jeong J; Wu J; Langone KC; Watson D
Clin Chem; 2007 Jun; 53(6):1084-91. PubMed ID: 17463177
[TBL] [Abstract][Full Text] [Related]
5. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
[TBL] [Abstract][Full Text] [Related]
6. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.
Kronenwett R; Bohmann K; Prinzler J; Sinn BV; Haufe F; Roth C; Averdick M; Ropers T; Windbergs C; Brase JC; Weber KE; Fisch K; Müller BM; Schmidt M; Filipits M; Dubsky P; Petry C; Dietel M; Denkert C
BMC Cancer; 2012 Oct; 12():456. PubMed ID: 23039280
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
8. Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material.
Peng Z; Andersson K; Lindholm J; Dethlefsen O; Pramana S; Pawitan Y; Nistér M; Nilsson S; Li C
PLoS One; 2016; 11(1):e0145545. PubMed ID: 26731648
[TBL] [Abstract][Full Text] [Related]
9. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer.
Greenland NY; Zhang L; Cowan JE; Carroll PR; Stohr BA; Simko JP
J Urol; 2019 Jul; 202(1):90-95. PubMed ID: 30810466
[TBL] [Abstract][Full Text] [Related]
10. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
11. New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.
Chu K; Corcoran N; Norden S; Wong LM
Anticancer Agents Med Chem; 2018; 18(7):951-957. PubMed ID: 29141559
[TBL] [Abstract][Full Text] [Related]
12. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
13. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.
Hessels D; Klein Gunnewiek JM; van Oort I; Karthaus HF; van Leenders GJ; van Balken B; Kiemeney LA; Witjes JA; Schalken JA
Eur Urol; 2003 Jul; 44(1):8-15; discussion 15-6. PubMed ID: 12814669
[TBL] [Abstract][Full Text] [Related]
14. A M-MLV reverse transcriptase with reduced RNaseH activity allows greater sensitivity of gene expression detection in formalin fixed and paraffin embedded prostate cancer samples.
Hagen RM; Rhodes A; Oxley J; Ladomery MR
Exp Mol Pathol; 2013 Aug; 95(1):98-104. PubMed ID: 23739432
[TBL] [Abstract][Full Text] [Related]
15. Analytical Performance of a Gene Expression Classifier for Medullary Thyroid Carcinoma.
Pankratz DG; Hu Z; Kim SY; Monroe RJ; Wong MG; Traweek ST; Kloos RT; Walsh PS; Kennedy GC
Thyroid; 2016 Nov; 26(11):1573-1580. PubMed ID: 27605259
[TBL] [Abstract][Full Text] [Related]
16. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
Schildgen V; Warm M; Brockmann M; Schildgen O
Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
[TBL] [Abstract][Full Text] [Related]
17. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
18. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate.
Gelmini S; Tricarico C; Petrone L; Forti G; Amorosi A; Dedola GL; Serio M; Pazzagli M; Orlando C
Clin Chem Lab Med; 2003 Mar; 41(3):261-5. PubMed ID: 12705330
[TBL] [Abstract][Full Text] [Related]
19. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer.
Okegawa T; Noda H; Kato M; Miyata A; Nutahara K; Higashihara E
Prostate; 2000 Aug; 44(3):210-8. PubMed ID: 10906737
[TBL] [Abstract][Full Text] [Related]
20. The analytical validation of the Oncotype DX Recurrence Score assay.
Baehner FL
Ecancermedicalscience; 2016; 10():675. PubMed ID: 27729940
[No Abstract] [Full Text] [Related]
[Next] [New Search]
